8102
-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Therapeutics and Clinical Risk Management
(2,215,700) Views
Editor in Chief Professor Garry Walsh
1178-203X
Automated estimated GFR reporting: A new tool to promote safer prescribing in patients with chronic kidney disease?
KPG Harris, Bernie Stribling
Therapeutics and Clinical Risk Management 2007, 3:969-972
23 November 2007
Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients
Hanne H Villesen, Anne-Marie Banning, Rasmus H Petersen, Sebatian Weinelt, Jesper B Poulsen, et al
Therapeutics and Clinical Risk Management 2007, 3:961-967
22 November 2007
Targeting CD22 as a strategy for treating systemic autoimmune diseases
Thomas Dörner, David M Goldenberg
Therapeutics and Clinical Risk Management 2007, 3:953-959
22 November 2007
Pharmacological causes of hyperprolactinemia
Daria La Torre, Alberto Falorni
Therapeutics and Clinical Risk Management 2007, 3:929-951
22 November 2007
Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
Prashant Kedia, Russell D Cohen
Therapeutics and Clinical Risk Management 2007, 3:919-927
22 November 2007
Use of zoledronic acid in the treatment of Paget’s disease
Margaret Seton, Stephen M Krane
Therapeutics and Clinical Risk Management 2007, 3:913-918
22 November 2007
Review
A systematic review of infliximab in the treatment of early rheumatoid arthritis
Sophie Martin Du Pan, Cem Gabay, Axel Finckh
Therapeutics and Clinical Risk Management 2007, 3:905-911
22 November 2007
The role of mesalamine in the treatment of ulcerative colitis
Raffi Karagozian, Robert Burakoff
Therapeutics and Clinical Risk Management 2007, 3:893-903
22 November 2007
Montelukast: its role in the treatment of childhood asthma
Koray Harmanci
Therapeutics and Clinical Risk Management 2007, 3:885-892
22 November 2007
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
Andrew J Armstrong, Daniel J George
Therapeutics and Clinical Risk Management 2007, 3:877-883
22 November 2007
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
Marco Merlano, Marcella Occelli
Therapeutics and Clinical Risk Management 2007, 3:871-876
22 November 2007
Oblimersen for the treatment of patients with chronic lymphocytic leukemia
Bruce D Cheson
Therapeutics and Clinical Risk Management 2007, 3:855-870
22 November 2007
Beta-adrenergic receptor antagonists and chronic heart failure in children
Sylvie Di Filippo
Therapeutics and Clinical Risk Management 2007, 3:847-854
22 November 2007
Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
Laurence Guy Howes
Therapeutics and Clinical Risk Management 2007, 3:831-845
22 November 2007
Chronic non-cancer pain: Focus on once-daily tramadol formulations
Flaminia Coluzzi, Consalvo Mattia
Therapeutics and Clinical Risk Management 2007, 3:819-829
22 November 2007
Decitabine in the treatment of myelodysplastic syndromes
Hussain I Saba
Therapeutics and Clinical Risk Management 2007, 3:807-817
22 November 2007
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective
Renzo Galanello
Therapeutics and Clinical Risk Management 2007, 3:795-805
22 November 2007
Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
Fiona Walsh
Therapeutics and Clinical Risk Management 2007, 3:789-794
22 November 2007
Clinical and molecular aspects of glucocorticoid resistant asthma
Chris J Corrigan, Tuck-Kay Loke
Therapeutics and Clinical Risk Management 2007, 3:771-787
22 November 2007
Postprandial insulin resistance as an early predictor of cardiovascular risk
W Wayne Lautt
Therapeutics and Clinical Risk Management 2007, 3:761-770
21 November 2007
A critical analysis of barriers to the clinical implementation of pharmacogenomics
Ross A McKinnon, Michael B Ward, Michael J Sorich
Therapeutics and Clinical Risk Management 2007, 3:751-759
21 November 2007
Naltrexone long-acting formulation in the treatment of alcohol dependence
Bankole A Johnson
Therapeutics and Clinical Risk Management 2007, 3:741-749
21 November 2007
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
Shyam Sundar, Piero L Olliaro
Therapeutics and Clinical Risk Management 2007, 3:733-740
21 November 2007
The use of dorzolamide versus other hypotensive agents to prevent glaucomatous progression
Savvas Diafas, Douglas G Day, Jeanette A Stewart, William C Stewart
Therapeutics and Clinical Risk Management 2007, 3:725-732
21 November 2007
The role of tramadol in current treatment strategies for musculoskeletal pain
Stephan A Schug
Therapeutics and Clinical Risk Management 2007, 3:717-723
21 November 2007
Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas
Daniela A Bota, Annick Desjardins, Jennifer A Quinn, Mary L Affronti, Henry S Friedman
Therapeutics and Clinical Risk Management 2007, 3:707-715
21 November 2007
Editorial Foreword || FREE PAPER ||
Garry M Walsh
Therapeutics and Clinical Risk Management 2007, 3:705-706
21 November 2007
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
